Search for Clinical Trial Results
Liposarcoma - 50 Studies Found
Status | Study |
Withdrawn |
Study Name: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma Condition: Dedifferentiated Liposarcoma Date: 2009-09-01 Interventions: Drug: IPI-504 IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatmen |
Active, not recruiting |
Study Name: Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Condition: Advanced and / or Metastatic Liposarcoma Date: 2012-09-14 Interventions: Drug: Pazopanib Patients will receive oral pazopanib, 800mg once daily and treatment will continue until |
Recruiting |
Study Name: Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Condition:
Date: 2014-09-05 Interventions: Drug: Trabectedin Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discret |
Completed |
Study Name: A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Condition: Advanced Liposarcoma or Leiomyosarcoma Date: 2011-04-26 Interventions:
|
Recruiting |
Study Name: A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Condition:
|
Terminated |
Study Name: Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Condition: Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma Date: 2012-10-29 Interventions: Drug: plitidepsin |
Completed |
Study Name: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Condition:
Date: 2010-09-24 Interventions: Drug: Palbociclib Treatment will consist of either: |
Recruiting |
Study Name: Study of Abemaciclib in Dedifferentiated Liposarcoma Condition:
Date: 2016-07-25 Interventions: Drug: Abemaciclib Other Name: LY2835219 |
Active, not recruiting |
Study Name: A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma Condition:
Date: 2015-10-06 Interventions: Drug: ribociclib Oral, 600 mg x 1 a day, duration - according to response |